耐受性质粒抑制人肽酰精氨酸脱亚胺酶4免疫所触发的自身抗体产生
研究在人肽酰精氨酸脱亚胺酶4(hPAD4)免疫的C3H小鼠模型中,测试编码hPAD4及TGF-β1、IL-10、IL-2的耐受性质粒能否阻断抗瓜氨酸化肽抗体产生。结果显示该质粒显著抑制对hPAD4的T细胞活化,并降低针对精氨酸肽和瓜氨酸化肽的抗体产生。作者认为对hPAD4的耐受化可能有助于关闭类风湿关节炎中的ACPA。
要点
- 编码hPAD4及TGF-β1、IL-10、IL-2的耐受性质粒在hPAD4免疫C3H小鼠中显著抑制T细胞活化。
- 该质粒降低hPAD4免疫小鼠对精氨酸肽和瓜氨酸化肽的抗体产生。
- 作者认为对hPAD4耐受化可能有助于关闭类风湿关节炎中的ACPA。
核心结论
- 对hPAD4耐受化可减少hPAD4免疫小鼠中抗瓜氨酸化肽抗体的产生。
- 作者认为对hPAD4的耐受化可能有助于关闭类风湿关节炎中的ACPA。
研究设计与样本
- 在hPAD4免疫后产生抗瓜氨酸化肽抗体的C3H小鼠模型中,测试编码hPAD4及TGF-β1、IL-10、IL-2的耐受性质粒。
- 对照质粒为编码TGF-β1、IL-10、IL-2的质粒,或不含hPAD4及细胞因子的质粒。
- 用流式细胞术分析注射质粒的hPAD4免疫小鼠中T细胞活化。
- 用含33条精氨酸肽及其136个瓜氨酸取代变体的肽阵列,分析hPAD4免疫小鼠注射质粒前后的自身抗体谱。
主要发现
- 在hPAD4免疫C3H小鼠中注射编码hPAD4及TGF-β1、IL-10、IL-2的质粒,显著抑制对hPAD4的T细胞活化。
- 该质粒降低hPAD4免疫小鼠对精氨酸肽和瓜氨酸化肽的抗体产生。
关键数值与推荐
- 肽阵列包含33条含精氨酸肽及其136个瓜氨酸取代变体。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Rheumatoid arthritis (RA) is usually preceded and likely mediated by autoantibodies to citrullinated proteins (ACPAs) that recognize citrulline residues on multiple proteins. Conversion of arginine into citrulline is performed by enzymes called peptidyl arginine deiminases (PADs). We have previously demonstrated that the human PAD4 (hPAD4) is a T cell target whose recognition provides help for the production of ACPAs by a hapten/carrier mechanism. Human PAD4 is thus an attractive therapeutic target to stop ACPA production. Here, we tested whether tolerization to hPAD4 may block the production of anti-citrullinated peptide antibodies. METHODS: We used a tolerogenic plasmid encoding hPAD4 and transforming growth factor (TGF) β1, interleukin (IL) 10, and IL-2 in a model where C3H mice immunized with hPAD4 develop anti-citrullinated peptide antibodies. As controls, we used a plasmid encoding TGF-β1, IL-10, IL-2, or a plasmid without hPAD4 or cytokines. T cell activation in hPAD4-immunized mice injected with plasmids was analyzed by flow cytometry. Autoantibody profile was analyzed in hPAD4-immunized mice before and after plasmid injection by peptide array using 33 arginine-containing peptides and their 136 citrulline-substituted variants. RESULTS: Injection of the plasmid encoding hPAD4 and TGF-β1, IL-10, and IL-2 in hPAD4-immunized C3H mice significantly inhibited the T cell activation to hPAD4 and decreased antibody production to arginine and citrullinated peptides. CONCLUSIONS: Tolerizing to hPAD4 decreases the production of anti-citrullinated peptide antibodies in mice immunized with hPAD4. This suggests that tolerization to hPAD4 may allow one to switch off ACPAs in RA.
引用
- Pagni PP, Kumar V, Lambert NC, et al. A Tolerogenic Plasmid Inhibits Autoantibody Production Triggered by Immunization With Human Peptidyl Arginine Deiminase 4. Arthritis Rheumatol. 2025. PMID: 40551392. doi:10.1002/art.43295
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。